Home » News » Drug Sponsors » Endo to acquire NuPathe

Endo to acquire NuPathe

Wednesday, December 18, 2013

Endo Health Solutions, a U.S.-based specialty healthcare company, has entered into a definitive agreement to acquire NuPathe, a specialty pharmaceutical company focused on neuroscience solutions for central nervous system diseases, for $2.85 per share in cash, or approximately $105 million. 

In addition, NuPathe shareholders will receive rights to receive additional cash payments of up to $3.15 per share if specified net sales of NuPathe’s migraine treatment ZECUITY are achieved over time. 

ZECUITY, which was approved by the FDA in January for the acute treatment of migraine with or without aura in adults, is the first and only FDA-approved prescription migraine patch.  It is a disposable, single-use, battery-powered transdermal patch that actively delivers sumatriptan, a widely prescribed migraine medication, through the skin. ZECUITY provides relief of both migraine headache pain and migraine-related nausea (MRN), and was approved based on an extensive development program with phase III trials that included 793 patients using nearly 10,000 ZECUITY patches.  In these trials, ZECUITY demonstrated a favorable safety profile and was effective at relieving migraine headache pain and migraine-related nausea two hours after patch activation.

The transaction is expected to be completed in early 2014.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!